• Пологи і ведення пологів у ВІЛ-інфікованих жінок. Думка комітету експертів Американського коледжу акушерів і гінекологів
До змісту

Пологи і ведення пологів у ВІЛ-інфікованих жінок. Думка комітету експертів Американського коледжу акушерів і гінекологів

HEALTH OF WOMAN. 2018.8(134):120–124

Номер 751 (Замінює думку Комітету № 234, травень 2000 г.)
Комітет з акушерській практиці
Робоча група експертів з ВІЛ
Скорочений варіант. Адаптовано – С.О. Шурпяк


1. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O’Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331:1173–80.

2. Mofenson LM, Lambert JS, Stiehm ER, Bethel J, Meyer WA III, Whitehouse J, et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. N Engl J Med 1999;341:385–93.

3. Garcia PM, Kalish LA, Pitt J, Minkoff H, Quinn TC, Burchett SK, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med 1999;341:394–402.

4. Townsend CL, Byrne L, Cortina-Borja M, Thorne C, de Ruiter A, Lyall H, et al. Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000–2011. AIDS 2014;28:1049–57.

5. Kind C, Rudin C, Siegrist CA, Wyler CA, Biedermann K, Lauper U, et al. Prevention of vertical HIV transmission: additive protective effect of elective Cesarean section and zidovudine prophylaxis. Swiss Neonatal HIV Study Group. AIDS 1998;12:205–10.

6. Mandelbrot L, Le Chenadec J, Berrebi A, Bongain A, Benifla JL, Delfraissy JF, et al. Perinatal HIV-1 transmission: interaction between zidovudine prophylaxis and mode of delivery in the French Perinatal Cohort. JAMA 1998;280: 55–60.

7. Elective caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial. European Mode of Delivery Collaboration [published erratum appears in Lancet 1999;353:1714]. Lancet 1999;353:1035–9.

8. Andiman W, Bryson Y, de Martino M, Fowler M, Harris D, Hutto C, et al. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1-a meta-analysis of 15 prospective cohort studies. International Perinatal HIV Group. N Engl J Med 1999;340: 977–87.

9. Briand N, Jasseron C, Sibiude J, Azria E, Pollet J, Hammou Y, et al. Cesarean section for HIV-infected women in the combination antiretroviral therapies era, 2000–2010. Am J Obstet Gynecol 2013;209:335.e1–12.

10. Scott RK, Chakhtoura N, Burke MM, Cohen RA, Kreitchmann R. Delivery after 40 weeks of gestation in pregnant women with well-controlled human immunodeficiency virus. Obstet Gynecol 2017;130:502–10.

11. Panel on treatment of HIV-infected pregnant women and prevention of perinatal transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Rockville (MD): Department of Health and Human Services; 2017. Available at: https://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf. Retrieved January 26, 2018.

12. Medically indicated late-preterm and early-term deliveries. Committee Opinion No. 560. American College of Obstetricians and Gynecologists. Obstet Gynecol 2013;121:908– 10.

13. Rodman JH, Flynn PM, Robbins B, Jimenez E, Bardeguez AD, Rodriguez JF, et al. Systemic pharmacokinetics and cellular pharmacology of zidovudine in human immuno deficiency virus type 1-infected women and newborn infants. J Infect Dis 1999;180:1844–50.

14. Briand N, Warszawski J, Mandelbrot L, Dollfus C, Pannier E, Cravello L, et al. Is intrapartum intravenous zidovudine for prevention of mother-to-child HIV-1 transmission still useful in the combination antiretroviral therapy era? ANRS-EPF CO1-CO11 Study Group. Clin Infect Dis 2013;57:903–14.

15. Myer L, Phillips TK, McIntyre JA, Hsiao NY, Petro G, Zerbe A, et al. HIV viraemia and mother-to-child transmission risk after antiretroviral therapy initiation in pregnancy in Cape Town, South Africa. HIV Med 2017;18: 80–8.

16. Duration of ruptured membranes and vertical transmission of HIV-1: a meta-analysis from 15 prospective cohort studies. International Perinatal HIV Group. AIDS 2001;15:357– 68.

17. Mark S, Murphy KE, Read S, Bitnun A, Yudin MH. HIV mother-to-child transmission, mode of delivery, and duration of rupture of membranes: experience in the current era. Infect Dis Obstet Gynecol 2012;2012:267969.

18. Cotter AM, Brookfield KF, Duthely LM, Gonzalez Quintero VH, Potter JE, O’Sullivan MJ. Duration of membrane rupture and risk of perinatal transmission of HIV-1 in the era of combination antiretroviral therapy. Am J Obstet Gynecol 2012;207:482.e1–5.

19. Peters H, Byrne L, De Ruiter A, Francis K, Harding K, Taylor GP, et al. Duration of ruptured membranes and mother-to-child HIV transmission: a prospective population-based surveillance study. BJOG 2016;123:975– 81.

20. Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000–2006. AIDS 2008;22:973–81.

21. Jamieson DJ, Read JS, Kourtis AP, Durant TM, Lampe MA, Dominguez KL. Cesarean delivery for HIV-infected women: recommendations and controversies. Am J Obstet Gynecol 2007;197:S96–100.

22. Nielsen TF, Hokegard KH. Postoperative cesarean section morbidity: a prospective study. Am J Obstet Gynecol 1983; 146:911–6.

23. Semprini AE, Castagna C, Ravizza M, Fiore S, Savasi V, Muggiasca ML, et al. The incidence of complications after caesarean section in 156 HIV-positive women. AIDS 1995; 9:913–7.

24. Bulterys M, Chao A, Dushimimana A, Saah A. Fatal complications after Cesarian section in HIV-infected women. AIDS 1996;10:923–4.

25. Mandelbrot L, Mayaux MJ, Bongain A, Berrebi A, Moudoub-Jeanpetit Y, Benifla JL, et al. Obstetric factors and mother-to-child transmission of human immunodeficiency virus type 1: the French perinatal cohorts. SEROGEST French Pediatric HIV Infection Study Group. Am J Obstet Gynecol 1996;175:661–7.

26. Shapiro DE, Sperling RS, Mandelbrot L, Britto P, Cunningham BE. Risk factors for perinatal human immunodeficiency virus transmission in patients receiving zidovudine prophylaxis. Pediatric AIDS Clinical Trials Group protocol 076 Study Group. Obstet Gynecol 1999;94:897–908.

27. Navarro J, Curran A, Burgos J, Torrella A, Ocaña I, Falcó V, et al. Acute leg ischaemia in an HIV-infected patient receiving antiretroviral treatment. Antivir Ther (Lond) 2017;22:89–90.

28. Update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings. Centers for Disease Control (CDC). MMWR Morb Mortal Wkly Rep 1988;37:377–82, 387–8.

29. Prenatal and perinatal human immunodeficiency virus testing. ACOG Committee Opinion No. 752. American College of Obstetricians and Gynecologists. Obstet Gynecol 2018;132:e138–42.